Skip to main content

Recent Scientific Presentations

2015

  • Introduction to Fragment Based Drug Discovery
    Christopher Smith
    BIT 5th UCLA, January 20, 2015 Los Angeles, California

2014

  • Fragment Based Drug Discovery. Sweating the Small Stuff is Worth it
    Gavin Hirst
    BIT 5th International Conference on Medicinal Chemistry, November 18-20, 2014 Shanghai, China
  • High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875
    Gyorgy Snell
    PSDI 2014 Protein Structure Determination in Industry, November 2-4, 2014 Lisbon, Portugal
  • Fragment Based Lead Generation: Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase
    Christopher Smith
    Fragment Based Lead Discovery Conference 2014, September 21-24, 2014 Basel, Switzerland
  • Structural Insights Into Allosteric Agonist Bound human GPR40 (hGPR40)
    Ankita Srivastava
    September 10, 2014
  • Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation
    Steven Woodhead
    XXIII EFMC-ISMC Symposium, September 9, 2014 Lisbon, Portugal
  • The Impact of Compound Properties on Attrition Risk
    Matthew Marx
    Gordon Research Seminar, August 2, 2014
  • Fragment Based Lead Generation: A Rich Source for Designing Selective Bruton's Tyrosine Kinase Inhibitors
    Mark Sabat
    Zing Conference, July 19-22, 2014 Punta Cana, Dominican Republic
  • How Safe is your Drug? - The Toxicologist's Race from Discovery to IND
    Raymond Liu
    CACO-PBSS (Pharmaceutical and BioScience Society), June 27, 2014 La Jolla, California
  • Preformulation Approaches to Enhance Solubility/Bioavailability of Poorly Soluble Drug Candidates
    Rongliang Chen
    The 2nd Drug Formulation & Bioavailability West Conference, June 2-3, 2014 San Diego, California
  • Process Research and Kilogram Synthesis of TAK-733, an Investigational, Potent MEK inhibitor
    Yuxin Zhao
    Cambridge Healthtech Institute's 7th International Efficient Process Chemistry Meeting, May 22-23, 2014 Boston, Massachusetts
  • Use of Fragment-based drug design in the discovery of two series of potent methionine aminopeptidase-2 inhibitors
    Christopher McBride
    CHI Drug Discovery Chemistry Meeting, April 22-13, 2014 San Diego, California
  • UCSD lectures on biologics
    Aaron Chamberlain
    UCSD, April 2, 2014 San Diego, California
  • Discovery of Nesina - The Whole Story
    Betty Lam
    March 27, 2014
  • The Challenge of ADC Target Identification & Validation
    Patrick Vincent
    World ADC Frankfurt, February 20, 2014 Frankfurt, Germany
  • The Role of Analytics in the Design and Control of Antibody Drug Conjugates
    Samadhi Vitharana
    Cambridge Health Institute's 13th Annual PEP Talk, January 13-17 Palm Springs, California
  • Discovery of a small molecule inhibitor of Burton's Tyrosine Kinase (BTK) for autoimmune diseases
    Loui Madakamutil

2013

  • Accelerating Drug-target simulations in Lipid Bilayers with GPUs
    Andrew Jennings
    GPU Conference, November 5-6, 2013 San Diego, California
  • Machine Learning Applications with Jchem
    Steve Wilkens
    ChemAxon, September 24, 2013
  • Extracting Chemical Knowledge From Patents
    Steve Wilkens
    ChemAxon, September 24, 2013
  • An Introduction to Fragment Based Drug Discover
    Christopher Smith
    Academics to Industry, July 23, 2013
  • A review of strategies to interrogate p38? and JNK1 using affinity-based methods and FBDD
    Steve Swann
    July 17, 2013
  • SFC method development for scale up purification: UPC2/MS vs. parallel SFC/MS
    Lu Zeng
    June 26, 2013
  • From high throughput to high difficulty: the evolution of protein crystallography for drug discovery
    Gyorgy Snell
    APS User Meeting, May 9, 2013
  • Process Chemistry - Roles and Objectives in Support of Drug Development Programs
    Wolfgang Notz
    March 11, 2013
  • High-resolution Structure Of GPR40 Receptor Bound To Partial Agonist TAK-875 (Fasiglifam)
    Ankita Srivastava
    GPCR Workshop, 2013

2012

  • Discovery of NESINA (alogliptin), a Highly Selective Dipeptidyl Peptidase-IV inhibitor for the Treatment of Type 2 Diabetes
    Robert Wynands
    12th International Kyoto Conference on New Aspects of Organic Chemistry, November, 12, 2012 Kyoto, Japan
  • tructure-Based Drug Design - Increasing the Likelihood to Create New Medicines
    Kathleen Aertgeerts
    10th Annual Congress of International Drug Discovery Science and Technology, November 8-10, 2012 Hanjing, China
  • Impact of Machine Learning in Predictive ADME and Kinase Selectivity
    Steve Wilkens
    UKQSAR Conference, November 8, 2012 Cambridge University
  • Recent Developments in the Carcinogenicity Assessment of the Biotechnology-derived Pharmaceuticals
    Ronald Steigerwalt
    American College of Toxicology, November 6, 2012
  • Evaluation of New UPC2/MS System
    Lu Zeng
    September 27, 2012
  • Just Another Chemical Query Tool or Not
    Matthew Pustelnik
    ChemAxon User Group Meeting, September 25-26, 2012 Boston, Massachusetts
  • Compound Progression Workflow
    Matthew Pustelnik
    ChemAxon User Group Meeting, September 25-26, 2012 Boston, Massachusetts
  • Structure based drug design and optimization of potent inhibitors of Polo-like Kinase 1 (PLK1)
    Christopher McBride
    Technical Achievements in Organic Chemistry Award Symposium, August 22, 2012 Philadelphia, Pennsylvania
  • An Analytical Toolbox for Rapid Formulation Development of a Monoclonal Antibody
    Kamal Kannan
    CACO Pharmaceutical and Bioscience Society, August 10, 2012
  • Advanced SFC/MS technologies to support drug discovery and development
    Lu Zeng
    June 29, 2012
  • The Application of Calorimetry in Fragment Drug Discovery
    Yiqin Wu
    Biacore/ITC User Conference, 2012 San Diego, California

2011

  • Discovery of TAK-960: an Orally Available Small Molecule Inhibitor of Polo-Like Kinase 1 (Plk1)
    Zhe Nie
    242nd ACS National Meeting, August 28, 2011 Denver, CO
  • Developing an Analytical Methods Platform to Support ADCs - Finding the Optimal Antibody Drug Combination
    Mike Buckley
    World ADC Summit, February 21, 2011 Frankfurt, Germany
  • The Influence of Antigen, Antibody and ADC Properties in In Vitro and In Vivo Cytotoxicity
    Gregory Landes
    Antibody Drug Products Meeting at CHI PepTalk, January 10, 2011 San Diego, CA

2010

  • Development of New Chiral Chromatographic Methods for the Analysis and Purification of Pharmaceutical Samples
    Lu Zeng
    Chirality 2010, July 11 -15, 2010 Sapporo, Japan
  • Discovery of NesinaTM, a Potent DPP-4 Inhibitor for the Treatment of Diabetes Mellitus Type 2, using Structural Enzymology Approaches
    Kathleen Aertgeerts
    EMBO Conference Series: Catalytic Mechanisms by Biological Systems: at the interface between chemistry and biology, May 7, 2010 Hamburg, Germany
  • Fragment-based discovery of TAK-901, a novel multi-targeted Aurora B kinase inhibitor
    Ron de Jong
    101st AACR Annual Meeting, April 17-21, 2010 Washington, DC
  • Antibody Target Discovery
    Mary Haak-Frendscho
    4 Annual Proteins Congress, April 4th, 2010 London, England